Welcome to our dedicated page for Eliem Therapeutics SEC filings (Ticker: ELYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eliem Therapeutics’ disclosures can feel like a lab notebook written in legalese—hundreds of pages on R&D burn, clinical milestones, and shelf registrations that move the share count overnight. If you are searching for Eliem Therapeutics SEC filings explained simply, this page turns dense reports into clear, actionable insights.
Our AI reviews every submission the moment it hits EDGAR. Whether it is an Eliem Therapeutics annual report 10-K simplified that breaks down CD19-antibody trial costs, an Eliem Therapeutics quarterly earnings report 10-Q filing highlighting cash runway, or an Eliem Therapeutics 8-K material events explained summarizing interim study data, you get a concise brief plus the full document. Real-time alerts flag Eliem Therapeutics Form 4 insider transactions real-time so you can track executive stock moves alongside detailed Eliem Therapeutics insider trading Form 4 transactions tables. Still comparing compensation packages? Our platform links directly to the Eliem Therapeutics proxy statement executive compensation section.
Here’s how professionals use these tools:
- Run instant Eliem Therapeutics earnings report filing analysis to gauge clinical spending trends.
- Set notifications for Eliem Therapeutics executive stock transactions Form 4 before pivotal data releases.
- Follow every immunology program update through AI-tagged exhibits in 10-Q, 10-K, and 8-K forms.
- Save hours by understanding Eliem Therapeutics SEC documents with AI rather than parsing footnotes manually.
Every filing—10-K, 10-Q, 8-K, S-3, even the latest Eliem Therapeutics proxy statement—is indexed, summarized, and updated in real time. Complex biotech disclosures become clear so you can focus on making informed decisions, not decoding jargon.
Hovnanian Enterprises, Inc. (HOV) – Form 4 insider transaction
Director Edward A. Kangas reported the sale of 5,500 shares of the company’s Class A common stock on 30 Jun 2025 at a weighted average price of $107.121 per share. Following the disposition, his direct holdings declined from 10,838 to 5,338 shares. No derivative security transactions were reported, and no 10b5-1 trading plan was indicated.
Climb Bio, Inc. (CLYM) – Form 4 insider filing
On 20 June 2025, Senior Vice President of Finance Cindy Driscoll reported the receipt of a new equity award dated 17 June 2025. The award consists of 200,000 non-qualified stock options with an exercise price of $1.20 per share and a ten-year term expiring 16 June 2035.
Vesting schedule: 25 % (50,000 options) vest on the first anniversary of the grant date; the remaining 150,000 options vest in 36 equal monthly instalments through 17 June 2029, conditioned on continued service.
Following the grant, the reporting person now holds 200,000 derivative securities (options) directly. No open-market purchases or sales of common stock were reported, and there was no cash outlay for the grant (grant price recorded as $0).
The filing represents a routine incentive-based award intended to align executive interests with shareholders; it has a modest dilutive potential relative to the company’s total share count.
Kronos Bio, Inc. (KRON) filed a Form 4 reporting that director Taiyin Yang disposed of her equity interests on 20 Jun 2025 in connection with the company’s acquisition by Concentra Biosciences.
Common shares: 11,333 shares were tendered at $0.57 per share, the cash component of the Concentra offer. Each tendered share also entitled the holder to one non-transferable contingent value right (CVR) under the merger agreement.
Stock options: All outstanding options (total underlying shares: 131,350) with exercise prices ranging from $0.95 to $28.58 were automatically disposed/cancelled. Under the merger terms, options with an exercise price below $0.57 receive a cash payment equal to the spread plus one CVR per underlying share, while options at or above $0.57 were cancelled for no consideration.
The filing confirms that the tender offer closed on 18 Jun 2025 and the subsequent merger made Kronos Bio a wholly owned subsidiary of Concentra. Following consummation, KRON shares are expected to cease trading, and future value for former shareholders hinges on CVR payments tied to post-closing milestones defined in the CVR Agreement.
- Reporting person’s post-transaction holdings: 0 shares and 0 options, indicating a full exit.
- Ownership form: All securities were held directly.
- Regulatory context: Filing satisfies Section 16 reporting obligations for insiders upon disposition of securities in a change-of-control transaction.
FAQ
What is the current stock price of Eliem Therapeutics (ELYM)?
What is the market cap of Eliem Therapeutics (ELYM)?
What is the core focus of Eliem Therapeutics, Inc?
Which therapeutic areas are targeted by the Company?
How does Eliem Therapeutics generate revenue?
What distinguishes Eliem Therapeutics from other biotech companies?
Where are the Company’s key operations located?
How does the Company ensure the quality of its clinical research?
What are the risks associated with investing in a clinical-stage biotech company like Eliem?
How can investors stay informed about the Company’s progress?
